Arsanis, which is developing antibodies designed to prevent serious infectious diseases, raised $40 million by offering 4 million shares at $10, below the initial $15 to $17 range. Arsanis plans to list on the Nasdaq under the symbol ASNS. Citi, Cowen & Company and Piper Jaffray acted as lead managers on the deal.
